BELLUS Health Inc. Announces $12 Million Rights Offering To Common Sh...( To the extent shareholders do not exe...),Health

To the extent shareholders do not exercise rights under the offering, the holdings of the standby purchasers will be increased accordingly.

The rights offering will result in the reduction of the conversion price of the convertible notes of BELLUS Health due in 2026, render such notes immediately convertible and result in the reduction of the conversion price of the convertible notes due in 2014 held by VSVI and Vitus and the reduction of the exercise price of certain of the outstanding warrants of BELLUS Health.

This press release is not an offer to sell or a solicitation of an offer to buy any securities of the Corporation.

THE SECURITIES WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "1933 ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmac
'/>"/>